Shenyang Xingqi Pharmaceutical Co Ltd
Shenyang Xingqi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of ophthalmic medications in the People's Republic of China. The company provides myopia prevention and control medications, nutrition and corneal repair drugs, ophthalmic anti-inflammatory/anti-infective drugs, artificial tears and eye lubricants, ophthalmic non-steroidal anti-inflammatory drugs… Read more
Shenyang Xingqi Pharmaceutical Co Ltd (300573) - Net Assets
Latest net assets as of September 2025: CN¥1.86 Billion CNY
Based on the latest financial reports, Shenyang Xingqi Pharmaceutical Co Ltd (300573) has net assets worth CN¥1.86 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.42 Billion) and total liabilities (CN¥562.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.86 Billion |
| % of Total Assets | 76.76% |
| Annual Growth Rate | 15.42% |
| 5-Year Change | 129.54% |
| 10-Year Change | 308.72% |
| Growth Volatility | 24.05 |
Shenyang Xingqi Pharmaceutical Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Shenyang Xingqi Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shenyang Xingqi Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual net assets of Shenyang Xingqi Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.59 Billion | -5.73% |
| 2023-12-31 | CN¥1.69 Billion | +8.86% |
| 2022-12-31 | CN¥1.55 Billion | +15.46% |
| 2021-12-31 | CN¥1.34 Billion | +93.71% |
| 2020-12-31 | CN¥694.06 Million | +20.73% |
| 2019-12-31 | CN¥574.90 Million | +3.67% |
| 2018-12-31 | CN¥554.58 Million | +0.22% |
| 2017-12-31 | CN¥553.38 Million | +6.23% |
| 2016-12-31 | CN¥520.95 Million | +33.65% |
| 2015-12-31 | CN¥389.79 Million | +5.98% |
| 2014-12-31 | CN¥367.81 Million | +9.21% |
| 2013-12-31 | CN¥336.80 Million | +15.86% |
| 2012-12-31 | CN¥290.70 Million | +17.69% |
| 2011-12-31 | CN¥247.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shenyang Xingqi Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4394.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥463.78 Million | 29.11% |
| Common Stock | CN¥175.25 Million | 11.00% |
| Other Components | CN¥954.14 Million | 59.89% |
| Total Equity | CN¥1.59 Billion | 100.00% |
Shenyang Xingqi Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Shenyang Xingqi Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pylon Technologies Co. Ltd. A
SHG:688063
|
$1.62 Billion |
|
Sugi Holdings Co.Ltd
PINK:SGIPF
|
$1.62 Billion |
|
Shenzhen Honor Electronic Co Ltd
SHE:300870
|
$1.62 Billion |
|
The GEO Group Inc
F:GEG
|
$1.62 Billion |
|
Songcheng Performance Develop
SHE:300144
|
$1.62 Billion |
|
Aerospace Hi-Tech Holding Group Co Ltd
SHE:000901
|
$1.62 Billion |
|
Sinbon Electronics Co Ltd
TW:3023
|
$1.62 Billion |
|
RXO Inc.
NYSE:RXO
|
$1.62 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shenyang Xingqi Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,689,920,857 to 1,593,168,346, a change of -96,752,511 (-5.7%).
- Net income of 338,061,784 contributed positively to equity growth.
- Dividend payments of 466,573,730 reduced retained earnings.
- Share repurchases of 319,609 reduced equity.
- Other factors increased equity by 32,079,044.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥338.06 Million | +21.22% |
| Dividends Paid | CN¥466.57 Million | -29.29% |
| Share Repurchases | CN¥319.61K | -0.02% |
| Other Changes | CN¥32.08 Million | +2.01% |
| Total Change | CN¥- | -5.73% |
Book Value vs Market Value Analysis
This analysis compares Shenyang Xingqi Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.67x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 17.06x to 7.67x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥4.09 | CN¥69.78 | x |
| 2012-12-31 | CN¥4.86 | CN¥69.78 | x |
| 2013-12-31 | CN¥5.63 | CN¥69.78 | x |
| 2014-12-31 | CN¥6.17 | CN¥69.78 | x |
| 2015-12-31 | CN¥6.56 | CN¥69.78 | x |
| 2016-12-31 | CN¥8.64 | CN¥69.78 | x |
| 2017-12-31 | CN¥6.84 | CN¥69.78 | x |
| 2018-12-31 | CN¥6.79 | CN¥69.78 | x |
| 2019-12-31 | CN¥5.08 | CN¥69.78 | x |
| 2020-12-31 | CN¥8.35 | CN¥69.78 | x |
| 2021-12-31 | CN¥15.70 | CN¥69.78 | x |
| 2022-12-31 | CN¥12.52 | CN¥69.78 | x |
| 2023-12-31 | CN¥13.60 | CN¥69.78 | x |
| 2024-12-31 | CN¥9.10 | CN¥69.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shenyang Xingqi Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.22%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.40%
- • Asset Turnover: 0.91x
- • Equity Multiplier: 1.34x
- Recent ROE (21.22%) is above the historical average (11.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 14.43% | 18.70% | 0.71x | 1.08x | CN¥10.94 Million |
| 2012 | 15.03% | 20.58% | 0.51x | 1.44x | CN¥14.63 Million |
| 2013 | 13.69% | 21.08% | 0.39x | 1.68x | CN¥12.42 Million |
| 2014 | 8.43% | 12.18% | 0.38x | 1.82x | CN¥-5.77 Million |
| 2015 | 5.64% | 7.65% | 0.44x | 1.67x | CN¥-17.00 Million |
| 2016 | 10.42% | 16.01% | 0.47x | 1.38x | CN¥2.18 Million |
| 2017 | 7.17% | 10.95% | 0.53x | 1.23x | CN¥-15.60 Million |
| 2018 | 2.50% | 3.17% | 0.61x | 1.30x | CN¥-40.89 Million |
| 2019 | 6.31% | 6.62% | 0.64x | 1.50x | CN¥-20.96 Million |
| 2020 | 12.90% | 12.77% | 0.71x | 1.42x | CN¥19.76 Million |
| 2021 | 14.48% | 18.94% | 0.61x | 1.25x | CN¥60.25 Million |
| 2022 | 13.64% | 16.94% | 0.70x | 1.15x | CN¥56.45 Million |
| 2023 | 14.20% | 16.36% | 0.73x | 1.20x | CN¥71.04 Million |
| 2024 | 21.22% | 17.40% | 0.91x | 1.34x | CN¥178.74 Million |
Industry Comparison
This section compares Shenyang Xingqi Pharmaceutical Co Ltd's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,323,666,547
- Average return on equity (ROE) among peers: 12.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | CN¥1.86 Billion | 14.43% | 0.30x | $1.62 Billion |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $2.03 Billion | -9.26% | 2.64x | $356.80 Million |
| Blue Sail Medical Co Ltd (002382) | $10.54 Billion | 10.97% | 0.61x | $763.05 Million |
| Andon Health Co Ltd (002432) | $758.75 Million | 1.34% | 0.32x | $2.12 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $2.75 Billion | 15.67% | 0.82x | $346.13 Million |
| Guangzhou Improve Med Instrument (300030) | $592.55 Million | 4.90% | 0.10x | $234.74 Million |
| Shanghai Tofflon Science Tech (300171) | $2.41 Billion | 11.06% | 0.57x | $784.88 Million |
| Truking Technology Ltd (300358) | $320.32 Million | 29.77% | 1.35x | $545.42 Million |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $1.41 Billion | 16.14% | 0.58x | $438.45 Million |
| Autek China Inc (300595) | $105.24 Million | 28.59% | 0.10x | $1.21 Billion |